AstraZeneca PLC Filing of Form 20-F with SEC (9502R)
06 March 2019 - 6:01PM
UK Regulatory
TIDMAZN
RNS Number : 9502R
AstraZeneca PLC
06 March 2019
6 March 2019 07:00 GMT
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND
EXCHANGE COMMISSION
AstraZeneca PLC (the Company) announced today that, on 5 March
2019, it filed its 2018 Annual Report on Form 20-F with the US
Securities and Exchange Commission (SEC). The document is available
for viewing on the SEC website at www.sec.gov and also on the
Company's website at www.astrazeneca.com. The Company will send any
holder of the Company's securities, upon request, a hard copy of
the Company's complete audited financial statements free of charge.
Requests may be made by writing to the Company Secretary,
AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical
Campus, Cambridge, CB2 0AA, UK.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRSSAESIFUSESD
(END) Dow Jones Newswires
March 06, 2019 02:01 ET (07:01 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024
